TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04827095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Support and Education Program 1
Description: The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Support and Education Program 2
Description: The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
Study: NCT05278312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: A Home-based Exercise Program to improve strength and balance and prevent falls.
Study: NCT06567717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc has not previously been investigated in the treatment of IPF.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos for zinc and nicotinamide riboside
Description: These will be identical in appearance to the active substances

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside has not previously been investigated in the treatment of IPF.
Study: NCT05270512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
Study: NCT04806958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PulsePoint notification
Description: The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator.
Study: NCT05043220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG and PROM
Description: description will follow
Study: NCT05692739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: see arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: see arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: see arm description
Study: NCT06222879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080; SHR-A1811
Description: Participants will receive HRS-8080 and SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080; SHR-A2009
Description: Participants will receive HRS-8080 and SHR-A2009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009; SHR-1316
Description: Participants will receive SHR-A2009 and SHR-1316
Study: NCT05744219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06150872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DurVena Photochemical Tissue Passivation
Description: Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
Study: NCT05290805

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECMO flow rate reduction
Description: ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
Study: NCT06333041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
Study: NCT05680727

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
Study: NCT06581393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moda-flx Hemodialysis System
Description: All participants will complete up to 4 dialysis treatments on the Moda-flx Hemodialysis System over a period of up to 2 weeks.
Study: NCT05678101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation (TENS)
Description: Chattanooga Physio TENS (DJO Global, Vista, CA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation (TENS)
Description: Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
Study: NCT05819645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid intake not as per standard guidlines
Description: The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fluid intake not as per standard guidlines
Description: The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
Study: NCT04730973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lipid-lowering therapy (LLT)
Description: lipid-lowering therapy (LLT)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lipid-lowering therapy (LLT)
Description: lipid-lowering therapy (LLT)
Study: NCT05019638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia group
Description: bupivacaine 0.25% with epinephrine 1:400,000.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local multimodal analgesia group
Description: 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
Study: NCT05905874

Intervention type: OTHER
Intervention: Machine learning-based prediction model
Description: The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.

Intervention type: OTHER
Intervention: Machine learning-based prediction model
Description: The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
Study: NCT05740839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT Exercise Program
Description: Exercise program with stationary bike via the Zoom platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Usual Activities
Study: NCT05183685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telecare consultation
Description: Participants will use zoom to communicate with the doctors in clinic.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Usual face to face consultation
Description: Participants will have face-to-face communication with the doctors in clinic.
Study: NCT06232733

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyles Project e-intervention
Description: Virtual lifestyle behaviour change support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Project e-intervention
Description: Virtual lifestyle behaviour change support.
Study: NCT06364826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, bevacizumab, gemcitabine
Description: This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT
Study: NCT05841017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy with Immersive Virtual Reality support.
Description: Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
Study: NCT06075602

Intervention type: DEVICE
Intervention: Impact of current PCI techniques/ devices in complex coronary artery lesions
Description: To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
Study: NCT05331378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses
Description: A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Single vision lenses
Description: A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
Study: NCT04977804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The interventions are a form or exercise, specifically resistance exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric plus blood-flow restriction
Description: Eccentric plus blood-flow restriction
Study: NCT05383131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: Mulltiple doses of HEC585 for up to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: Mulltiple doses of HEC585 for up to 10 days
Study: NCT05370352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised chat messaging
Description: Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS text messaging
Description: SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.
Study: NCT06070701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial Parasternal Block (SIPB)
Description: Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (ESPB)
Description: Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: During general anesthesia, fentanyl is administered according to NOL monitoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: During general anesthesia, fentanyl is administered according to NOL monitoring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
Study: NCT06553131

Intervention type: DEVICE
Intervention: Neuromuscular Transmission Monitoring
Description: A neuromuscular transmission module connected to electrodes applied to the skin and positioned to provide stimulation of a single nerve and monitor the muscular response to nerve stimulation
Study: NCT04014296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: 16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
Study: NCT06080503

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LT-SABR
Description: 42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
Study: NCT06543056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES014
Description: ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
Study: NCT03923907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIM intervention group
Description: As in arm description
Study: NCT05922592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crestal sinus lift using ballon technique
Description: The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crestal sinus lift using densah burs
Description: The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
Study: NCT06566560

Intervention type: OTHER
Group type: OTHER
Intervention: redispensing oral anticancer drugs
Description: Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them.~Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:~1. the seal bag is unopened~2. the drug package is unopend and undamaged~3. the expiry date is ≥ 3 months~4. the medication has not been stored outside the product label storage claim~Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy.
Study: NCT05864287

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bodies in motion intervention program
Description: Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
Study: NCT06454695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future-oriented imagery rescripting
Description: In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Psychotherapy and/or medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Psychotherapy and/or medication
Study: NCT06216080

Intervention type: OTHER
Intervention: D-FF-OCT analysis of CVC
Description: Dynamic full-field optical coherence tomography analysis of central venous catheter sections to better apprehend strucural characterization of central venous catheter-deposited biofilm
Study: NCT06313697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2102 injection
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2102 injection
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2102 injection
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2102 injection
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2102 injection
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2102 injection
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose
Study: NCT06569004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: randomised study, two group (experimental and control)
Description: Use of IR beam before peripheral intravenous catheter application
Study: NCT05138614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication for Opioid Use Disorder
Description: medication management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication for Opioid Use Disorder
Description: medication management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication for Opioid Use Disorder
Description: medication management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication for Opioid Use Disorder
Description: medication management

Intervention type: OTHER
Group type: OTHER
Intervention: Medication for Opioid Use Disorder
Description: medication management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Critical Time Intervention
Description: offering intensive community-based services that decrease in intensity over time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Critical Time Intervention
Description: offering intensive community-based services that decrease in intensity over time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Critical Time Intervention
Description: offering intensive community-based services that decrease in intensity over time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Peer Support
Description: including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Peer Support
Description: including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
Study: NCT05383131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Mulltiple doses of Pirfenidone for up to 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Mulltiple doses of Nintedanib for up to 7 days